Stockreport

TEVA Signs Deal With RPRX to Accelerate Development of Vitiligo Drug [Yahoo! Finance]

Royalty Pharma plc - Class A Ordinary Shares  (RPRX) 
US:NASDAQ Investor Relations: ir.reprosrx.com/investor-relations
PDF accelerate the development of Teva's anti-IL-15 antibody, TEV-'408. IL-15 plays a central role in driving multiple immune-mediated disease pathways. The candidate is cur [Read more]